Vivani Medical, Inc.
VANIHealthcare|Biotechnology|US
$1.07
+0.03 (+2.88%)
Tangible Book / Share
$0.22
Cash / Share
$0.23
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05670379 Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Overweight and Obesity, Type2diabetes | P1 | Completed | 24 | RCT, Open-label | Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL |
| NCT07430059 Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | Obesity & Overweight | P1 | Not Yet Recruiting | 20 | RCT, Open-label | Semaglutide (Wegovy) weekly injection |